AzTrials
AzTrials

CancerNCT07825090

Association of ICU Admission Time, Age Stratification, and Clinical Frailty Scale With 30-Day Mortality in Geriatric Oncology Patients

An observational study of Cancer and Frailty, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Geriatric oncology patients frequently require intensive care admission and are at increased risk of adverse outcomes due to advanced age, frailty, and critical illness. Delays in admission from the emergency department to the intensive care unit (ICU) may further contribute to poor prognosis. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Cancer, Frailty, Mortality
What is being tested?
Observation
How many people
150 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jan 2026to 1 Nov 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: Geriatric oncology patients aged 65 years and older who were admitted from the Emergency Department to the Anesthesiology and Reanimation Intensive Care Unit between January 1, 2026 and July 1, 2026.

Who may be able to join

  • Age ≥ 65 years
  • Diagnosis of solid or hematologic malignancy
  • Admission from the Emergency Department to the Anesthesiology and Reanimation Intensive Care Unit
  • ICU admission between January 1, 2026 and July 1, 2026

Who cannot join

  • Age < 65 years
  • Missing data regarding boarding time, Clinical Frailty Scale score, or 30-day mortality
  • Readmission to the ICU during the same hospitalization
  • Patients transferred from hospital wards or other ICUs

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Ankara Dr. Abdurrahman Yurtaslan Oncolgy Training and Research Hospital

    Yenimahalle, Ankara, 0620

Other trials in Turkey (Türkiye)

About this study

Official title: Association of Time to Intensive Care Unit Admission, Age Stratification, and Clinical Frailty Scale With 30-Day Mortality in Geriatric Oncology Patients Admitted From the Emergency Department to the Anesthesiology and Reanimation Intensive Care Unit

Geriatric oncology patients frequently require intensive care admission and are at increased risk of adverse outcomes due to advanced age, frailty, and critical illness. Delays in admission from the emergency department to the intensive care unit (ICU) may further contribute to poor prognosis. This retrospective cohort study aims to evaluate the association of ICU admission time, age stratification, and Clinical Frailty Scale (CFS) score with 30-day mortality among geriatric cancer patients admitted from the emergency department to the Anesthesiology and Reanimation Intensive Care Unit. Secondary objectives include assessing the relationship of these factors with intensive care unit length of stay, hospital length of stay, and in-hospital mortality. The findings may contribute to improved risk stratification and optimization of critical care management in geriatric oncology patients.

Read the detailed description

Geriatric oncology patients admitted from the emergency department to the intensive care unit (ICU) represent a particularly vulnerable population with a high risk of mortality due to advanced age, malignancy-related immunosuppression, multiple comorbidities, and reduced physiological reserve. Limited ICU bed capacity and the increasing burden of critically ill patients have made appropriate triage and timely ICU admission increasingly important in this patient group.

Recent studies have demonstrated that delays in ICU admission from the emergency department (boarding time) are significantly associated with increased 30-day mortality. In particular, delays ranging from 5 to 12 hours have been shown to exhibit a dose-response relationship, with mortality risk increasing in parallel with prolonged waiting times. Similarly, studies conducted in critically ill oncology patients have identified delayed ICU admission and ICU triage decisions made during off-hours as independent predictors of 30-day mortality. These findings suggest that multidisciplinary ICU triage during regular working hours and a lower threshold for ICU admission in critically ill oncology patients may improve clinical outcomes.

Furthermore, prolonged emergency department boarding before ICU admission has consistently been associated with adverse clinical outcomes and increased mortality among critically ill patients. Therefore, minimizing delays in ICU admission may represent an important strategy for improving prognosis in this high-risk population.

Despite these observations, there remains a paucity of data evaluating the independent effects of boarding time, Clinical Frailty Scale (CFS) score, and age on 30-day mortality in geriatric oncology patients. Therefore, the primary objective of this study is to investigate the independent associations of emergency department boarding time, CFS score, and age with 30-day mortality among oncology patients aged 65 years and older admitted from the emergency department to the Anesthesiology and Reanimation Intensive Care Unit (ARICU).

Patients will be stratified into three age groups: 65-74 years, 75-84 years, and ≥85 years. This classification is expected to provide a more detailed assessment of the impact of age-related differences in biological and physiological reserve, as well as tolerance to oncological treatments, on clinical outcomes.

The relationships between boarding time, CFS score, age, and 30-day mortality will be analyzed using multivariable statistical models adjusted for potential confounding variables, including disease severity indices such as the Sequential Organ Failure Assessment (SOFA) score and/or Acute Physiology and Chronic Health Evaluation II (APACHE II) score, cancer type and stage, comorbidity burden, and organ support therapies.

The findings of this study are expected to contribute to the optimization of ICU admission processes, improve risk stratification, and enhance understanding of the prognostic importance of early intensive care intervention in geriatric oncology patients. In addition, the results may provide a scientific basis for the development of evidence-based ICU admission and patient selection criteria for this high-risk population.

Being tested
Observation
Keywords
Geriatric Oncology, Clinical Frailty Scale, Emergency Department Boarding Time, İntensive Care Unit, 30-Day Mortality, ICU Admission Delay, Critical Care
Medical subject headings
Neoplasms, Frailty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ObservationOther

    Retrospective observational assessment of emergency department boarding time, Clinical Frailty Scale score, age stratification, and their association with 30-day mortality in geriatric oncology patients admitted to the Anesthesiology and Reanimation Intensive Care Unit.

Study groups in NCT07825090
Study groupRoleWhat they receive
Geriatric Oncology PatientsPatients aged 65 years and older with a diagnosis of cancer who were admitted from the emergency department to the Anesthesiology and Reanimation Intensive Care Unit between January 1, 2026 and July 1, 2026.
Receives: Other: Observation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 30-Day All-Cause Mortality

    All cause mortality within 30 days after admission to the Anesthesiology and Reanimation Intensive Care Unit

    Measured: 30 days

Secondary outcomes (5)
  1. Emergency Department Boarding Time

    Time elapsed between emergency department admission and intensive care unit admission, calculated as the difference between the recorded admission times.

    Measured: At intensive care unit admission

  2. Pre-Admission Clinical Frailty Scale (CFS) Score

    Baseline frailty status prior to the acute illness leading to intensive care unit admission will be assessed using the Clinical Frailty Scale (CFS), ranging from 1 (very fit) to 9 (terminally ill), with higher scores indicating greater frailty. The association between the pre-admission CFS score and 30-day mortality will be evaluated.

    Measured: Baseline, prior to the acute illness leading to intensive care unit admission

  3. Clinical Frailty Scale Score According to Age Group

    Pre-admission Clinical Frailty Scale (CFS) scores will be compared across predefined age groups (65-74 years, 75-84 years, and ≥85 years). CFS ranges from 1 (very fit) to 9 (terminally ill), with higher scores indicating greater frailty.

    Measured: Baseline, prior to the acute illness leading to intensive care unit admission.

  4. Intensive Care Unit Length of Stay

    Duration of stay in the intensive care unit measured in days from ICU admission to ICU discharge.

    Measured: At intensive care unit discharge

  5. 30-Day All-cause Mortality According to Age Group

    30 day all-cause mortality will be compared across predefined age groups (65-74 years, 75-84 years, and ≥85 years)

    Measured: From the date of ICU admission until death from any cause, assessed up to 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Sep 2026
  2. Study start1 Jan 2026
  3. Primary completion1 Jul 2026
  4. Study completion1 Nov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07825090
Sponsor's protocol ID
AOH2026-07/156
Status last verified
Sep 2026
First submitted
9 Aug 2026
Last updated
17 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Cancer and Frailty, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

30-Day All-Cause Mortality (time frame: 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in